XBI156.31 +0.81%IBB218.14 +0.44%S&P 5007,619.38 +1.31%NASDAQ 10028,374.25 +2.28%DOW 3052,486.49 +0.49%FTSE 10010,864.47 +0.27%
Biotech Today Subscribe

Biotechnology Today · FDA & Regulation

FDA Clears Lynch’s Under-Eye Injection for Phase IIb Study

Lynch Regenerative Medicine can advance its investigational under-eye injection into a controlled study, but safety and efficacy remain unproven.

Desmond Achterberg · 6 min read
FDA Clears Lynch’s Under-Eye Injection for Phase IIb Study

Key facts

  • Regulatory milestone: FDA authorization of Lynch Regenerative Medicine’s IND for a Phase IIb trial
  • Investigational treatment: Injectable rhPDGF-BB for infraorbital hollowing
  • Study design: Multi-center, randomized controlled study evaluating safety and preliminary efficacy in up to 75 participants
  • Announcement date: Oct. 21, 2026

The FDA authorized Lynch Regenerative Medicine’s investigational new drug application for a Phase IIb study of injectable rhPDGF-BB for infraorbital hollowing in up to 75 participants.

Lynch Regenerative Medicine, LLC has received FDA authorization to advance an investigational injectable treatment for infraorbital hollowing into a Phase IIb clinical trial. The planned study will evaluate rhPDGF-BB in up to 75 participants, moving the program toward a controlled assessment of safety and preliminary efficacy.

The authorization is a clinical-development milestone, not permission to market the treatment. Its immediate significance is that the company can proceed with the study under its investigational new drug application, or IND. Whether the injection provides a meaningful benefit, and whether its risks are acceptable for this use, remain questions for clinical testing.

Lynch announced the authorization on Oct. 21, 2026, describing a multi-center, randomized controlled study, according to PR Newswire Biotech. No clinical results accompanied the milestone.

Authorization opens a study, not a commercial market

An IND provides a regulatory framework for investigating a treatment in people. FDA authorization allows the proposed research to proceed; it does not establish that the product works or that patients should receive it outside the appropriate investigational setting. That distinction matters particularly when a development announcement concerns an appearance-related condition and may attract attention from potential patients.

Infraorbital hollowing refers to a hollowed appearance beneath the eyes. Lynch is investigating an injection of rhPDGF-BB for that use. The announcement identifies the treatment and the target condition, but it does not supply evidence of improvement, the duration of any benefit or a demonstrated safety profile from this planned trial.

The Phase IIb designation identifies the development stage. It should not be read as a substitute for results. The stated goals are safety and preliminary efficacy, meaning the study is intended to examine both potential harms and early evidence that the treatment delivers its intended effect.

For the company, the regulatory step creates an opportunity to generate evidence that could inform subsequent development decisions. It does not settle the eventual regulatory pathway, establish a launch date or support a commercial revenue forecast.

Randomization makes the comparison more useful

The planned randomized controlled design is central to the study’s usefulness. Randomization assigns participants to study groups by chance, helping reduce the risk that differences between the groups explain an apparent treatment effect. A control group provides a reference against which investigators can assess what happens after treatment.

Those features can make a study more informative than observations of treated patients alone. An apparent improvement can be difficult to interpret without a comparison, especially when evaluating changes in appearance. A controlled design is intended to help distinguish a treatment-related effect from changes that might otherwise occur.

However, the description does not identify the control intervention or say whether participants and assessors will be blinded to treatment assignment. Those are important details to watch for. A randomized trial can be designed in different ways, and the label alone does not reveal how the study will manage expectations or assess outcomes.

However, the description does not identify the control intervention or say whether participants and assessors will be blinded to treatment assignment.

The multi-center structure means the research is planned across more than one site. That can allow the treatment to be evaluated in different clinical settings. It also makes consistency important: differences in administration, participant selection or assessment could complicate the interpretation of results unless the protocol addresses them.

Safety and visible benefit need separate evidence

The trial’s enrollment ceiling of 75 participants defines its planned scale, not the number already enrolled or treated. The announcement does not establish that recruitment has begun or that anyone has received the investigational injection in this study. Authorization, enrollment and completed follow-up are distinct milestones.

A study of this size may provide useful initial information, but its findings will need to be interpreted within the limits of the participants enrolled and the length of observation. Safety findings from a limited trial cannot automatically resolve questions about less common adverse effects or outcomes after broader use.

For efficacy, the key issue will be how improvement is defined and measured. In research on an appearance-related condition, the choice of assessment method matters. Investigator evaluations, patient assessments and standardized visual documentation can answer different questions; the available trial description does not specify which measures Lynch will use.

Duration also matters. Evidence of a change at an assessment visit would not, by itself, establish how long that change lasts. Likewise, favorable safety observations over a short interval would not establish a longer-term safety profile. These are considerations for interpreting eventual results, not findings about rhPDGF-BB.

The next milestones are operational and clinical

The next useful disclosures would clarify study execution: when recruitment begins, who is eligible, what the comparator is and how treatment response will be assessed. The dosing approach, follow-up schedule and handling of adverse events would also help explain what the study can reasonably establish.

For potential participants, eligibility requirements and the consent process will matter more than the development label alone. Investigational treatment carries uncertainty, and trial participation should not be confused with access to a proven cosmetic intervention. The present announcement offers no basis for promising an individual outcome.

For investors and potential development partners, the authorization reduces uncertainty about whether this proposed study can proceed. It does not remove clinical risk. The more consequential evidence will be whether Lynch can execute the trial and produce results that support further development, with benefits and harms evaluated together.

The distinction keeps the milestone in proportion: Lynch has secured permission to test an injectable approach for under-eye hollowing in a randomized controlled setting. The program’s next test is the evidence that study produces, rather than the authorization itself.

Frequently asked questions

What did the FDA authorize for Lynch Regenerative Medicine?

The FDA authorized Lynch Regenerative Medicine’s investigational new drug application for a Phase IIb clinical trial of injectable rhPDGF-BB for infraorbital hollowing. The authorization allows the proposed research to proceed. It is not marketing approval and does not establish that the treatment is safe or effective for this use.

What will the Phase IIb trial evaluate?

The planned trial will evaluate safety and preliminary efficacy of injectable rhPDGF-BB in up to 75 participants with infraorbital hollowing. It is described as a multi-center, randomized controlled study. The announcement does not specify the exact efficacy measures, control intervention, dosing approach or duration of follow-up.

What is infraorbital hollowing?

Infraorbital hollowing describes a hollowed appearance beneath the eyes. It is the condition targeted by Lynch Regenerative Medicine’s planned study of injectable rhPDGF-BB. The FDA authorization permits clinical investigation of that proposed use; it does not demonstrate that the injection improves the appearance of the under-eye area.

Why does the randomized controlled design matter?

Randomization assigns participants to study groups by chance, helping limit differences that could distort comparisons. A control group gives investigators a reference for interpreting outcomes. Together, these features can strengthen evidence about treatment effects, although the study’s usefulness also depends on its comparator, assessment methods, execution and follow-up.

Have participants already been enrolled or treated?

The announcement establishes FDA authorization and a planned enrollment of up to 75 participants, but it does not establish that recruitment or treatment has begun. Authorization, enrollment and completed follow-up are separate milestones. Additional disclosures would be needed to determine the study’s operational status and expected completion timing.

What should readers watch for next?

The most useful next disclosures would describe recruitment, eligibility, the control intervention, outcome measures and follow-up. Ultimately, safety findings and evidence of meaningful benefit will matter more than the authorization alone. The announcement provides no clinical results, commercial launch date or basis for forecasting an individual patient’s outcome.

Sources

Photo: newarta · Pixabay Content License — source

Filed under Biotechnology Today FDA & Regulation

The Biotech Today briefing

Trials, approvals and the deals moving biotech, in your inbox. Free.

Unsubscribe from any email. See our privacy policy.